Landscapes / Companies
Incyte Corporation not checked
FollowEvery new trial, moved date and filing, and a Monday email
Furthest along
6 approved
4 in Phase 3
Drugs
19
in active trials · 45 in all
Trials
53 active
215 since 2021
Drugs19
| Drug | How it works | Partner | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
Janus kinase inhibitor |
Approved in the EU | 20 Nov 2026soonPhase 2 trial completes | |||
| How it works | Blocks JAK enzymes that pass on immune signals | ||||
| Next date | 20 Nov 2026 · Phase 2 trial completes | ||||
| Also tested for | Hidradenitis Suppurativa (HS), NonSegmental Vitiligo and 2 more | ||||
| Open drug page | |||||
Programmed death receptor-1 blocking antibody |
Approved | 1 Jan 2027Phase 1 trial completes | |||
| How it works | Releases a brake on the immune system (PD-1 or PD-L1) so it attacks cancer cells | ||||
| Next date | 1 Jan 2027 · Phase 1 trial completes | ||||
| Also tested for | Solid Tumors | ||||
| Open drug page | |||||
Monoclonal antibody |
Incyte · Syndax Pharmaceuticals |
Approved | 6 Jan 2027Phase 1/2 trial completes | ||
| How it works | An antibody | ||||
| Next date | 6 Jan 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Chronic Graft-versus-host-disease | ||||
| Open drug page | |||||
Ruxolitinibnot checked |
Kinase Inhibitor; janus kinase inhibitor |
Incyte · Novartis Pharmaceuticals |
Approved | 30 Apr 2027Phase 3 trial completes | |
| How it works | Blocks JAK enzymes that pass on immune signals | ||||
| Next date | 30 Apr 2027 · Phase 3 trial completes | ||||
| Also tested for | Hidradenitis Suppurativa, Myeloproliferative Neoplasms and 16 more | ||||
| Open drug page | |||||
Monoclonal antibody |
MorphoSys |
Approved | 29 Aug 2027Phase 2 trial completes | ||
| How it works | An antibody | ||||
| Next date | 29 Aug 2027 · Phase 2 trial completes | ||||
| Also tested for | Diffuse Large B-cell Lymphoma, Non Hodgkins Lymphoma and 5 more | ||||
| Open drug page | |||||
Kinase inhibitor |
Approved | 25 Feb 2031Phase 2 trial completes | |||
| How it works | Blocks a kinase | ||||
| Next date | 25 Feb 2031 · Phase 2 trial completes | ||||
| Also tested for | Unresectable Cholangiocarcinoma, Advanced/Metastatic Cholangiocarcinoma | ||||
| Open drug page | |||||
— |
Phase 3 | 27 Apr 2027Phase 2 trial completes | |||
| Next date | 27 Apr 2027 · Phase 2 trial completes | ||||
| Also tested for | Ovarian Cancer, Renal Impairment and 2 more | ||||
| Open drug page | |||||
— |
Phase 3 | 15 Sep 2028Phase 3 trial completes | |||
| Next date | 15 Sep 2028 · Phase 3 trial completes | ||||
| Also tested for | Solid Tumors, Hepatic Insufficiency and 3 more | ||||
| Open drug page | |||||
— |
Phase 3 | 29 Dec 2028Phase 3 trial completes | |||
| Next date | 29 Dec 2028 · Phase 3 trial completes | ||||
| Also tested for | Solid Tumors, CRC (Colorectal Cancer) and 2 more | ||||
| Open drug page | |||||
— |
Phase 3 | 15 Jun 2029Phase 3 trial completes | |||
| Next date | 15 Jun 2029 · Phase 3 trial completes | ||||
| Also tested for | Myeloproliferative Neoplasms, Essential Thrombocythemia | ||||
| Open drug page | |||||
— |
Phase 2 | 30 Jul 2027Phase 2 trial completes | |||
| Next date | 30 Jul 2027 · Phase 2 trial completes | ||||
| Also tested for | Fibrodysplasia Ossificans Progressiva (FOP) | ||||
| Open drug page | |||||
— |
Phase 2 | 23 Sep 2027Phase 2 trial completes | |||
| Next date | 23 Sep 2027 · Phase 2 trial completes | ||||
| Also tested for | Immune Thrombocytopenia | ||||
| Open drug page | |||||
— |
Phase 1 | 27 Mar 2027Phase 1 trial completes | |||
| Next date | 27 Mar 2027 · Phase 1 trial completes | ||||
| Also tested for | Solid Tumors | ||||
| Open drug page | |||||
— |
Phase 1 | 30 Apr 2027Phase 1 trial completes | |||
| Next date | 30 Apr 2027 · Phase 1 trial completes | ||||
| Also tested for | Myelofibrosis, Myelodysplastic Syndrome and 5 more | ||||
| Open drug page | |||||
— |
Phase 1 | 27 Jul 2027Phase 1 trial completes | |||
| Next date | 27 Jul 2027 · Phase 1 trial completes | ||||
| Also tested for | Solid Tumors | ||||
| Open drug page | |||||
— |
Phase 1 | 14 Mar 2028Phase 1 trial completes | |||
| Next date | 14 Mar 2028 · Phase 1 trial completes | ||||
| Also tested for | Myeloproliferative Neoplasms | ||||
| Open drug page | |||||
— |
Phase 1 | 18 Aug 2028Phase 1 trial completes | |||
| Next date | 18 Aug 2028 · Phase 1 trial completes | ||||
| Also tested for | Solid Tumors, Hematologic Malignancies | ||||
| Open drug page | |||||
— |
Phase 1 | 9 Oct 2028Phase 1 trial completes | |||
| Next date | 9 Oct 2028 · Phase 1 trial completes | ||||
| Also tested for | Myeloproliferative Neoplasms | ||||
| Open drug page | |||||
— |
Phase 1 | 24 May 2030Phase 1 trial completes | |||
| Next date | 24 May 2030 · Phase 1 trial completes | ||||
| Also tested for | Myeloproliferative Neoplasms | ||||
| Open drug page | |||||
No drugs match “”.
About
- No active trial
- 26 other drugs
- SEC filings
- None: it does not file with the US SEC
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 Industry-sponsored drug trials since 2021